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Routine coagulation tests have been used for many years in
the preoperative setting in the belief that they identify
patients who may have acquired or congenital bleeding dis-
orders, and on the assumption that testing will predict peri-
operative bleeding allowing treatment to be given and
prevent it. Coagulation ‘screens’ typically include the pro-
thrombin time (PT) and the activated partial thromboplastin
time (APTT). Both tests were originally developed to aid in the
diagnosis of inherited bleeding disorders such as haemo-
philia and were not intended as screening tests.
Activation of coagulation can be achieved through the intrin-
sic or the extrinsic pathway leading to activation of the common
pathway and conversion of fibrinogen to fibrin leading to clot
formation. Although the cascade model of coagulation is not
physiological, it is useful as a means to understand the mechan-
ism by which traditional coagulation tests detect coagulopa-
thies. The APTT activates plasma typically with substances
such as kaolin or silica which cause activation of the contact
pathway and, subsequently, the intrinsic and common coagu-
lation pathways. A deficiency in any of these pathways will
therefore prolong the APTT. The PT is activated with supraphy-
siological concentrations of tissue factor and detects FVII
deficiency and also deficiencies in the common pathway. Both
tests can also be prolonged by the presence of a lupus anticoa-
gulant, inhibitors such as anticoagulants, and acute conditions
associated with an acquired bleeding state.
Inherited coagulation defects are rare. The incidence of hae-
mophilia A and B is estimated at 1:50001 2 and 1:30 0003 male
births, respectively. Severe, clinically relevant, deficiencies of FII,
FV, FVII, FX, and fibrinogen are even rarer with an incidence
varying between 1:300 000 and 1:2 000 000,4 although this
may be higher in populations where consanguineous marriages
are more common. FXI deficiency is common in Ashkenazi Jews
with a prevalence of 8%5 but rare in a general population.4 The
majority of patients with these bleeding disorders will be aware
of their diagnosis through either a personal or family history of
bleeding and will be registered at specialized haemophilia
centres. Indiscriminate screening by routine coagulation
testing will therefore only very rarely identify previously unde-
tected individuals. In contrast, prolongation of the APTT is a
common occurrence with the most common reasons being
mild FXII deficiency and the presence of a lupus anticoagulant,
neither of which is associated with a bleeding tendency. Moder-
ate and severe FXII deficiency was found in 2.3% of otherwise
healthy Austrian blood donors6 and in 10.3% of patients under-
going cardiac surgery.7 Lupus anticoagulant can be found in
1.2–3.8% of healthy individuals, but the incidence increases
with age and chronic disease, and was found in up to 30% of
patients with systemic lupus erythematosus.8 The ability of a
lupus anticoagulant to prolong the APTT or PT depends on the
combination of reagents and analysers used and may therefore
vary between laboratories. Other causes of a prolonged APTT
not associated with a bleeding tendency include high molecular
weight kininogen deficiency and prekallikrein deficiency. Finally,
a normal range is calculated by the mean +2 standard devi-
ations of measurements in healthy, non-bleeding subjects
and by definition 2.5% of measurements in normal individuals
will show a prolonged clotting time. Therefore, if routine coagu-
lation testing is done to identify previously undiagnosed bleed-
ing disorders, it is much more likely to identify a prolonged
routine coagulation test that is not associated with a bleeding
tendency. In practice, this can lead to further unnecessary
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testing and postponement or delay of the surgery. To further
compound the situation, a normal routine test does not
exclude the presence of, sometimes severe, bleeding disorders.
The most common of these is mild von Willebrand disease.
Deficiency of von Willebrand factor can occur in up to 1% of
the population, but only 1:10 000 are estimated to have a clini-
cally significant bleeding disorder.9 Although FVIII may be
reduced in patients with von Willebrand disease who therefore
will have a prolonged APTT, in milder forms FVIII may be
normal and patients may not be detected by routine testing.
Mild haemophilia A or B may also be missed if an insensitive
reagent/analyser combination is used, or during an acute
phase response where a temporarily high FVIII level may
lead to shortening of the APTT. Other conditions that cannot
be detected by routine coagulation testing but may be associ-
ated with clinically significant bleeding include the rare inher-
ited bleeding disorders such as FXIII and alpha 2 antiplasmin
deficiency and platelet function disorders.
The British Committee for Standards in Haematology
(BCSH) has recently published guidelines on the use of the
PT and APTT in the preoperative setting based on a systematic
review of the literature.10 They included studies that enabled
the calculation of predictive values (PV) and likelihood ratios
(LR) of the coagulation tests and bleeding history for perio-
perative bleeding in paediatric ENT (six studies), general
surgery (two studies), and one study in adult ENT surgery.
Three studies were prospective and in total measurements
of more than 12 000 patients were included. They found
poor positive PV and low LR for bleeding with an abnormal
coagulation test, whereas the perioperative bleeding rates
were similar in patients with and without abnormal coagu-
lation tests. A similar conclusion was reached in a review of
studies of patients undergoing bronchoscopy, central vein
cannulation, angiography, liver and kidney biopsy, and para-
centesis.11 The BCSH guideline does not recommend the use
of routine coagulation tests to predict perioperative bleeding
risk in unselected patients before surgery or other invasive
procedures.10 The systematic review did not include studies
of intracranial, neurosurgical, or ophthalmic surgery due to a
paucity of data, and although testing may be more justified
in procedures with a higher risk from bleeding, the arguments
regarding poor sensitivity and specificity of these tests remain.
A bleeding history is subjective and common symptoms are
found in up to 25% of a healthy population without bleeding
disorders including epistaxis, gum bleeding, and post-partum
haemorrhage.9 The use of a standardized bleeding question-
naire has been suggested as being better than indiscriminate
coagulation testing as a screening tool for perioperative bleed-
ing,12 and there are suggestions that in patients with congeni-
tal bleeding disorders, a structured history is at least as
informative as laboratory testing to predict bleeding.13 14 The
BCSH guideline recommends that a bleeding history, including
family history, evidence of excessive post-traumatic or post-
surgical bleeding, and use of antithrombotic drugs should be
taken in all patients before surgery or invasive procedures.10
Therefore, based on the available evidence, a reasonable
approach to assessing the perioperative bleeding risk is
that a structured bleeding history is taken and coagulation
testing is undertaken only if there is concern about a bleed-
ing tendency arising from the history. This may then also
include referral to haematology to investigate disorders
that are not detected by routine testing. Testing, however,
should be considered in patients with acute conditions
potentially associated with a haemorrhagic tendency such
as liver disease, sepsis, diffuse intravascular coagulation, pre-
eclampsia, cholestasis, and poor nutritional states leading to
vitamin K deficiency.
Coagulation testing is often routinely undertaken in anti-
coagulated patients or patients to be started on anticoagu-
lants. The APTT is used to monitor unfractionated heparin,
lepirudin, bivalirudin, and argatroban whereas the INR is
used for the monitoring of coumarin anticoagulants. The
APTT and PT are insensitive to low molecular weight heparins,
fondaparinux and danaparoid. Although prolongation of the
APTT can occur at therapeutic doses of these agents, specific
anti-Xa measurements should be used to assess the degree
of anticoagulation, if necessary. Recently, two new oral antic-
oagulants, rivaroxaban and dabigatran, were licensed for
thromboprophylaxis after total hip and knee replacement
and they do not require routine monitoring. Rivaroxaban is
a direct anti-Xa inhibitor that can prolong both the PT and
APTT (PT more than APTT). Neither test is suitable to
monitor the degree of anticoagulation, although a specifi-
cally calibrated PT assay has been suggested, and also
more specialized assays that are not generally available.15
Dabigatran is a direct thrombin inhibitor that can also
prolong both the PT and APTT (APTT more than PT). Again,
neither of these tests is suitable for monitoring the degree
of anticoagulation, and although a normal APTT may indicate
that no or low plasma concentrations of dabigatran are
present, this depends on the reagent/analyser combination
used. A normal thrombin time is more likely to indicate
that no dabigatran is present and other more specialized,
but not generally available, tests such as the ecarin clotting
time have also been proposed.16
Finally, there is increasing interest in the possibility of peri-
operative monitoring of the effect of antiplatelet agents such
as aspirin and clopidogrel. Although various point-of-care
tests have been developed, there remain significant ques-
tions about their sensitivity, specificity, and ability to
predict bleeding,17 and none of these tests are therefore cur-
rently routinely recommended in the preoperative setting but
are the subject of ongoing studies.
In conclusion, we feel that indiscriminate use of routine
coagulation testing in the preoperative setting is not
helpful and may cause unnecessary further testing and
delay of surgery. Coagulation testing should be restricted to
well-defined circumstances:
† Patients with a family history of known inherited bleed-
ing disorders.
† Patients with a personal history of bleeding identified by
structured history taking or a family history of bleeding.
Ideally, these individuals should be investigated
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electively by a haematologist before any surgery or
invasive procedure.
† Patients with acute illnesses such as sepsis or con-
ditions that can be associated with a coagulopathy
such as chronic liver disease.
† Patients on some anticoagulants. As anticoagulants,
but not necessarily antiplatelet drugs,18 are stopped
before operation for elective surgery, coagulation
testing should only be required for emergency surgery.
When surgery is performed on anticoagulated patients,
appropriate testing can be useful in excluding over-
anticoagulation at the time of surgery.
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